GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Asset Turnover

NKGen Biotech (NKGen Biotech) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. NKGen Biotech's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. NKGen Biotech's Total Assets for the quarter that ended in Mar. 2024 was $16.40 Mil. Therefore, NKGen Biotech's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. NKGen Biotech's annualized ROE % for the quarter that ended in Mar. 2024 was 37.85%. It is also linked to ROA % through Du Pont Formula. NKGen Biotech's annualized ROA % for the quarter that ended in Mar. 2024 was -131.28%.


NKGen Biotech Asset Turnover Historical Data

The historical data trend for NKGen Biotech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Asset Turnover Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Asset Turnover
0.02 - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial - - - - -

Competitive Comparison of NKGen Biotech's Asset Turnover

For the Biotechnology subindustry, NKGen Biotech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Asset Turnover falls into.



NKGen Biotech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

NKGen Biotech's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (16.33+16.481)/ 2 )
=0/16.4055
=0.00

NKGen Biotech's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (16.481+16.316)/ 2 )
=0/16.3985
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


NKGen Biotech  (NAS:NKGN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

NKGen Biotech's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-21.528/-56.874
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-21.528 / 0)*(0 / 16.3985)*(16.3985/ -56.874)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.2883
=ROA %*Equity Multiplier
=-131.28 %*-0.2883
=37.85 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

NKGen Biotech's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-21.528/16.3985
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-21.528 / 0)*(0 / 16.3985)
=Net Margin %*Asset Turnover
= %*0
=-131.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


NKGen Biotech Asset Turnover Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.